Significantly increased CCL5/RANTES and CCR7 mRNA levels in localized scleroderma

Regulatory Peptides

Volumn 170, Issue 1-3, 2011, Pages 4-6

  Gambichler, Thilo ^a   Skrygan, Marina ^a   Labanski, Alexandra Anna ^a   Kolios, Antonios Georgios ^a   Altmeyer, Peter ^a   Kreuter, Alexander ^a  

^a RUHR UNIVERSITY BOCHUM   (Germany)

Author keywords

Chemokines; Cytokines; Localized scleroderma; Morphea

Indexed keywords

CHEMOKINE RECEPTOR CCR7; INTERLEUKIN 1ALPHA; INTERLEUKIN 1BETA; INTERLEUKIN 2; INTERLEUKIN 6; MESSENGER RNA; MONOCYTE CHEMOTACTIC PROTEIN 4; RANTES; TUMOR NECROSIS FACTOR ALPHA;

ADULT; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; ENZYME REGULATION; FEMALE; HUMAN; HUMAN TISSUE; LOCALIZED SCLERODERMA; MALE; MORPHEA; PRIORITY JOURNAL; PROTEIN EXPRESSION; SKIN BIOPSY;

ADULT; AGED; CASE-CONTROL STUDIES; CHEMOKINE CCL5; FEMALE; GENE EXPRESSION PROFILING; HUMANS; INTERLEUKINS; MALE; MIDDLE AGED; MONOCYTE CHEMOATTRACTANT PROTEINS; RECEPTORS, CCR7; RNA, MESSENGER; SCLERODERMA, LOCALIZED; TRANSCRIPTION, GENETIC; TUMOR NECROSIS FACTOR-ALPHA;

EID: 80955178358     PISSN: 01670115     EISSN: 18731686     Source Type: Journal    
DOI: 10.1016/j.regpep.2011.05.003     Document Type: Article

References (22)

1. Peterson L.S., Nelson A.M., Su W.P. Classification of morphea. Mayo Clin Proc 1995, 70:1068-1076.
2. Badea I., Taylor M., Rosenberg A., Foldvari M. Pathogenesis and therapeutic approaches for improved topical treatment in localized scleroderma and systemic sclerosis. Rheumatology (Oxford) 2009, 48:213-221.
3. Kreuter A., Hyun J., Skrygan M., Sommer A., Bastian A., Altmeyer P., et al. Ultraviolet A1-induced downregulation of human beta-defensins and interleukin-6 and interleukin-8 correlates with clinical improvement in localized scleroderma. Br J Dermatol 2006, 155:600-607.
4. Ihn H., Sato S., Fujimoto M., Kikuchi K., Takehara K. Demonstration of interleukin-2, interleukin-4 and interleukin-6 in sera from patients with localized scleroderma. Arch Dermatol Res 1995, 287:193-197.
5. Fertin C., Nicolas J.F., Gillery P., Kalis B., Banchereau J., Maquart F.X. Interleukin-4 stimulates collagen synthesis by normal and scleroderma fibroblasts in dermal equivalents. Cell Mol Biol 1991, 37:823-829.
6. Alecu M., Geleriu L., Coman G., Gǎlǎţescu L. The interleukin-1, interleukin-2, interleukin-6 and tumour necrosis factor alpha serological levels in localised and systemic sclerosis. Rom J Intern Med 1998, 36:251-259.
7. Yamamoto T. Chemokines and chemokine receptors in scleroderma. Int Arch Allergy Immunol 2006, 140:345-356.
8. Distler J.H., Akhmetshina A., Schett G., Distler O. Monocyte chemoattractant proteins in the pathogenesis of systemic sclerosis. Rheumatology (Oxford) 2009, 48:98-103.
9. Livak K.J., Schmittgen T.D. Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. Methods 2001, 25:402-408.
10. Kadono T., Kikuchi K., Ihn H., Takehara K., Tamaki K. Increased production of interleukin 6 and interleukin 8 in scleroderma fibroblasts. J Rheumatol 1998, 25:296-301.
11. Duncan M.R., Berman B. Stimulation of collagen and glycosaminoglycan production in cultured human adult dermal fibroblasts by recombinant human interleukin 6. J Invest Dermatol 1991, 97:686-692.
12. Nagaoka T., Sato S., Haregawa M., Ihn H., Takehara K. Serum levels of soluble interleukin 6 receptor and soluble gp130 are elevated in patients with localized scleroderma. J Rheumatol 2000, 27:1917-1921.
13. Kawaguchi Y., McCarthy S.A., Watkins S.C., Wright T.M. Autocrine activation by interleukin 1alpha induces the fibrogenic phenotype of systemic sclerosis fibroblasts. J Rheumatol 2004 Oct, 31(10):1946-1954.
14. Wolfe R.E., Brelsfold W.G. Soluble interleukin-2 receptors in systemic lupus erythematosus. Arthritis Rheum 1988, 31:729-735.
15. Degiannis D., Seibold J.R., Czarnecki M., Raskova J., Raska K. Soluble interleukin-2 receptors in patients with systemic sclerosis: clinical and laboratory correlations. Arthritis Rheum 1990, 33:375-380.
16. Varga J., Abraham D. Systemic sclerosis: a prototypic multisystem fibrotic disorder. J Clin Invest 2007, 117:557-567.
17. Wynn T.A. Cellular and molecular mechanisms of fibrosis. J Pathol 2008, 214:199-210.
18. Yanaba K., Muroi E., Yoshizaki A., Hara T., Ogawa F., Shimizu K., et al. Serum CXCL16 concentrations correlate with the extent of skin sclerosis in patients with systemic sclerosis. J Rheumatol 2009, 36:1917-1923.
19. Yanaba K., Yoshizaki A., Muroi E., Ogawa F., Asano Y., Kadono T., et al. Serum CCL23 levels are increased in patients with systemic sclerosis. Arch Dermatol Res 2011, 303:29-34.
20. Yanaba K., Yoshizaki A., Muroi E., Hara T., Ogawa F., Shimizu K., et al. CCL13 is a promising diagnostic marker for systemic sclerosis. Br J Dermatol 2010, 162:332-336.
21. Gambichler T., Yilmaz E., Höxtermann S., Kolios A., Moritz R., Bechara F.G., et al. CCL13 serum levels in systemic sclerosis patients and controls. Br J Dermatol Mar. 24 2011, [Epub ahead of print]. 10.1111/j.1365-2133.2011.10330.x.
22. Pierce E.M., Carpenter K., Jakubzick C., Kunkel S.L., Evanoff H., Flaherty K.R., et al. Idiopathic pulmonary fibrosis fibroblasts migrate and proliferate to CC chemokine ligand 21. Eur Respir J 2007, 29:1082-1093.